Sorafenib in treatment of patients with advanced hepatocellular carcinoma: A systematic review

Hepatobiliary and Pancreatic Diseases International

Volumn 11, Issue 5, 2012, Pages 458-466

  Zhang, Xin ^a   Yang, Xin Rong ^a   Huang, Xiao Wu ^a   Wang, Wei Min ^a   Shi, Ruo Yu ^a   Xu, Yang ^a   Wang, Zheng ^a   Qiu, Shuang Jian ^a   Fan, Jia ^a   Zhou, Jian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Advanced hepatocellular carcinoma; Sorafenib; Systematic review

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOXORUBICIN; OCTREOTIDE; PLACEBO; SORAFENIB; UFT;

ADVANCED CANCER; ALOPECIA; ANOREXIA; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER GROWTH; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; META ANALYSIS; NAUSEA; OVERALL SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VOMITING;

EID: 84867781169     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(12)60209-4     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538.
3. Borie F, Bouvier AM, Herrero A, Faivre J, Launoy G, Delafosse P, et al. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. J Surg Oncol 2008;98:505-509.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
5. Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010;22:391-398.
6. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-1327.
7. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100.
8. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
9. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844.
10. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
12. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
13. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:2154-2160.
14. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 2010;21:326-332.
15. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010;53:126-131.
16. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
17. Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So. LAR. study. Cancer Chemother Pharmacol 2010;66:837-844.
18. Higgins JPT, Green S, Collaboration C. Cochrane handbook for systematic reviews of interventions, Edtion ed: Wiley Online Library;2008.
19. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
20. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
22. Lu M, Chen Y, Cai C, Yi X. A pilot study: Sorafenib in patients with post liver transplant recurrence of HCC. Transplantation 2010;90:s266.
23. Cho SB, Rew HS, Seo TJ, Jeong HK, Park SY, Lee WS, et al. Comparison of sorafenib and radiotherapy in unresectable hepatocellular carcinoma patients whom transcatheter arterial chemoembolization was ineffective or unsuitable. Hepatol Int 2010;4:302.
24. Yau T, Chan P, Cheung FY, Lee AS, Yau TK, Choo SP, et al. 47LBA Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma. EJC Supplements 2009;7:20-21.
25. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, et al. Prospective, randomized, doubleblind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation-HeiLivCa [ISRCTN24081794]. BMC Cancer 2008;8:349.
26. Lencioni R, Zou J, Leberre M, Meinhardt G, Voliotis D, Bruix J, et al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediatestage hepatocellular carcinoma (SPACE). J Clin Oncol 2010; 28:178.
27. Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin 2010;31:1643-1648.
28. Bitzer M, Horger M, Ebert M, Ganten T, Woerns M, Hauns B, et al. First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study[C]. ASCO Meet Abstr 2010;28:e14661.
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
30. Raoul J, Cheng AL, Yu S, Yang T, Nadel A, Fang F, et al. Efficacy and safety of sorafenib (SOR) in patients (PTS) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP and Asia-Pacific (AP) trials by baseline (BL) transaminase (ALT/AST), Alpha-fetoprotein (AFP) and Bilirubin (BIL) levels. Ann Oncol 2010;21:viii236.
31. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
32. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009;115:428-436.
33. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010;55:2744-2755.
34. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-1795.
35. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-1961.
36. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930.
37. Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007;30:519-524.
38. Wood LS, Manchen B. Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clin J Oncol Nurs 2007;11: 649-656.